These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 37512051)

  • 1. Association of Non-Alcoholic Fatty Liver Disease and Metabolic-Associated Fatty Liver Disease with COVID-19-Related Intensive Care Unit Outcomes: A Systematic Review and Meta-Analysis.
    Jagirdhar GSK; Pattnaik H; Banga A; Qasba RK; Rama K; Reddy ST; Bucharles ACF; Kashyap R; Elmati PR; Bansal V; Bains Y; DaCosta T; Surani S
    Medicina (Kaunas); 2023 Jul; 59(7):. PubMed ID: 37512051
    [No Abstract]   [Full Text] [Related]  

  • 2. Association of non-alcoholic fatty liver and metabolic-associated fatty liver with COVID-19 outcomes: A systematic review and meta-analysis.
    Jagirdhar GSK; Qasba RK; Pattnaik H; Rama K; Banga A; Reddy ST; Flumignan Bucharles AC; Kashyap R; Elmati PR; Bansal V; Bains Y; DaCosta T; Surani S
    World J Gastroenterol; 2023 Jun; 29(21):3362-3378. PubMed ID: 37377589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic Associated Fatty Liver Disease Is Associated With an Increased Risk of Severe COVID-19: A Systematic Review With Meta-Analysis.
    Hegyi PJ; Váncsa S; Ocskay K; Dembrovszky F; Kiss S; Farkas N; Erőss B; Szakács Z; Hegyi P; Pár G
    Front Med (Lausanne); 2021; 8():626425. PubMed ID: 33777974
    [No Abstract]   [Full Text] [Related]  

  • 4. The Association of Metabolic-Associated Fatty Liver Disease with Clinical Outcomes of COVID-19: A Systematic Review and Meta-Analysis.
    Hayat U; Ashfaq MZ; Johnson L; Ford R; Wuthnow C; Kadado K; El Jurdi K; Okut H; Kilgore WR; Assi M; Siddiqui AA
    Kans J Med; 2022; 15():241-246. PubMed ID: 35899064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NAFLD determined by Dallas Steatosis Index is associated with poor outcomes in COVID-19 pneumonia: a cohort study.
    Moctezuma-Velázquez P; Miranda-Zazueta G; Ortiz-Brizuela E; Garay-Mora JA; González-Lara MF; Tamez-Torres KM; Román-Montes CM; Díaz-Mejía BA; Pérez-García E; Villanueva-Reza M; Chapa-Ibargüengoitia M; Uscanga-Domínguez L; Sifuentes-Osornio J; Ponce-de-León A; Kershenobich-Stalnikowitz D; Mota-Ayala B; Moctezuma-Velázquez C
    Intern Emerg Med; 2022 Aug; 17(5):1355-1362. PubMed ID: 35138548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of Severe COVID-19 Increased by Metabolic Dysfunction-associated Fatty Liver Disease: A Meta-analysis.
    Tao Z; Li Y; Cheng B; Zhou T; Gao Y
    J Clin Gastroenterol; 2021 Nov-Dec 01; 55(10):830-835. PubMed ID: 34406175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review and meta-analysis of cohort studies on the potential association between NAFLD/MAFLD and risk of incident atrial fibrillation.
    Zhou BG; Ju SY; Mei YZ; Jiang X; Wang M; Zheng AJ; Ding YB
    Front Endocrinol (Lausanne); 2023; 14():1160532. PubMed ID: 37476492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic associated fatty liver disease increases the severity of COVID-19: A meta-analysis.
    Pan L; Huang P; Xie X; Xu J; Guo D; Jiang Y
    Dig Liver Dis; 2021 Feb; 53(2):153-157. PubMed ID: 33011088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Outcomes Between Metabolic Dysfunction-Associated Fatty Liver Disease and Non-alcoholic Fatty Liver Disease: A Meta-Analysis.
    Virk GS; Vajje J; Virk NK; Mannam R; Rehman W; Ghobriel NG; Mian IU; Usama M
    Cureus; 2023 Aug; 15(8):e44413. PubMed ID: 37791219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating angiopoietin-like proteins in metabolic-associated fatty liver disease: a systematic review and meta-analysis.
    Ke Y; Liu S; Zhang Z; Hu J
    Lipids Health Dis; 2021 May; 20(1):55. PubMed ID: 34034750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic Associated Fatty Liver Disease (MAFLD) and COVID-19 Infection: An Independent Predictor of Poor Disease Outcome?
    Milivojević V; Bogdanović J; Babić I; Todorović N; Ranković I
    Medicina (Kaunas); 2023 Aug; 59(8):. PubMed ID: 37629728
    [No Abstract]   [Full Text] [Related]  

  • 12. The association between metabolic dysfunction-associated fatty liver disease and chronic kidney disease: A systematic review and meta-analysis.
    Agustanti N; Soetedjo NNM; Damara FA; Iryaningrum MR; Permana H; Bestari MB; Supriyadi R
    Diabetes Metab Syndr; 2023 May; 17(5):102780. PubMed ID: 37201293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of metabolic dysfunction-associated fatty liver disease and nonalcoholic fatty liver disease with advanced fibrosis in the death and intubation of patients hospitalized with coronavirus disease 2019.
    Vázquez-Medina MU; Cerda-Reyes E; Galeana-Pavón A; López-Luna CE; Ramírez-Portillo PM; Ibañez-Cervantes G; Torres-Vázquez J; Vargas-De-León C
    Hepatol Commun; 2022 Aug; 6(8):2000-2010. PubMed ID: 35438253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Observational Data Meta-analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD.
    Lim GEH; Tang A; Ng CH; Chin YH; Lim WH; Tan DJH; Yong JN; Xiao J; Lee CW; Chan M; Chew NW; Xuan Tan EX; Siddiqui MS; Huang D; Noureddin M; Sanyal AJ; Muthiah MD
    Clin Gastroenterol Hepatol; 2023 Mar; 21(3):619-629.e7. PubMed ID: 34871813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coronavirus disease 2019 severity in obesity: Metabolic dysfunction-associated fatty liver disease in the spotlight.
    Vasques-Monteiro IML; Souza-Mello V
    World J Gastroenterol; 2021 Apr; 27(16):1738-1750. PubMed ID: 33967554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Global Prevalence and Clinical Characteristics of Metabolic-associated Fatty Liver Disease: A Meta-Analysis and Systematic Review of 10 739 607 Individuals.
    Chan KE; Koh TJL; Tang ASP; Quek J; Yong JN; Tay P; Tan DJH; Lim WH; Lin SY; Huang D; Chan M; Khoo CM; Chew NWS; Kaewdech A; Chamroonkul N; Dan YY; Noureddin M; Muthiah M; Eslam M; Ng CH
    J Clin Endocrinol Metab; 2022 Aug; 107(9):2691-2700. PubMed ID: 35587339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-alcoholic fatty liver disease and clinical outcomes in patients with COVID-19: A comprehensive systematic review and meta-analysis.
    Singh A; Hussain S; Antony B
    Diabetes Metab Syndr; 2021; 15(3):813-822. PubMed ID: 33862417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short sleep duration and the risk of nonalcoholic fatty liver disease/metabolic associated fatty liver disease: a systematic review and meta-analysis.
    Yang J; Zhang K; Xi Z; Ma Y; Shao C; Wang W; Tang YD
    Sleep Breath; 2023 Oct; 27(5):1985-1996. PubMed ID: 36544011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic-associated fatty liver disease is associated with acute pancreatitis with more severe course: Post hoc analysis of a prospectively collected international registry.
    Váncsa S; Sipos Z; Váradi A; Nagy R; Ocskay K; Juhász FM; Márta K; Teutsch B; Mikó A; Hegyi PJ; Vincze Á; Izbéki F; Czakó L; Papp M; Hamvas J; Varga M; Török I; Mickevicius A; Erőss B; Párniczky A; Szentesi A; Pár G; Hegyi P;
    United European Gastroenterol J; 2023 May; 11(4):371-382. PubMed ID: 37062947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of circulating omentin level and metabolic-associated fatty liver disease: a systematic review and meta-analysis.
    Zhang Q; Chen S; Ke Y; Li Q; Shen C; Ruan Y; Wu K; Hu J; Liu S
    Front Endocrinol (Lausanne); 2023; 14():1073498. PubMed ID: 37139340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.